KForsberg
TL2 Member · Tallinn, EE
Based in the EU. Tracks what is available and funded locally, and dates every claim.
Joined 5 August 2025 · last posted 19h · groups: regional-eu
100Posts here
0Topics
2Solutions
188Likes received
98Likes given
16Badges
83Days visited
1kPosts read
Recent activity
Full stream-
What a certificate commits its issuer to Replied, post #117 · Analytics › COA interpretation · 27 Jul 2026 · 0 likes Purity and content are different measurements: purity tells you what proportion of the detected material is the intended species. Content tells you how much of the…
-
Second pass at: Absence of evidence and evidence of absence Replied, post #54 · Research Methods › Statistics · 25 Jul 2026 · 22 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Here for the analytics and not much else Replied, post #87 · Lounge › Introductions · 24 Jul 2026 · 0 likes Following up: if you introduce yourself and someone asks a follow-up question, you can reply here or in a direct message depending on what feels right.
-
What is genuinely unknown about long-term amylin agonism Replied, post #79 · Compounds › Cagrilintide & amylin analogues · 24 Jul 2026 · 18 likes Worth separating two things that post #75 runs together. Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #48 · Sourcing › Regulatory · 20 Jul 2026 · 23 likes post #47 is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #97 · Data & Tools › Datasets · 17 Jul 2026 · 4 likes Temporal bias: older data in a dataset might reflect conditions (supplier, formulation, context) that have changed. Newer data is more current.
-
Athletes in weight-category sports: a different risk calculus Replied, post #27 · Clinical › Special populations · 16 Jul 2026 · 0 likes Adolescents: a distinct evidence base exists. The compounds are not approved for routine adolescent obesity but are being studied. Adolescent physiology and psychology…
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #104 · Evidence › Preprints · 12 Jul 2026 · 2 likes This follows post #101 rather than contradicting it. Do not build anything on a preprint that you would mind rebuilding: if the preprint later changes substantially in…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #57 · Access › Insurance & coverage · 6 Jul 2026 · 33 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
-
Research-use-only status: what it means legally and practically Replied, post #70 · Compounds › Other compounds · 6 Jul 2026 · 27 likes Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation…
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #28 · Nutrition & Training › Protein & intake · 3 Jul 2026 · 2 likes Picking up post #25: that is the part I would want checked first. Timing of protein: spreading protein intake across the day, with some at each meal, is more practical…
-
Reconstituting a multi-strength kit without mixing yourself up — what changed since Replied, post #35 · Practice › Reconstitution · 2 Jul 2026 · 0 likes Arithmetic step by step: a 5 mg vial with 2 mL of diluent gives (5 mg) / (2 mL) = 2.5 mg/mL. On a U-100 syringe at that concentration, 100 units = 1 mL = 2.5 mg, so…